Edwards Lifesciences Corporation Common Stock vs Intuitive Surgical, Inc. — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $84.25 (market cap $49.44B), while Intuitive Surgical, Inc. trades at $415.51 (market cap $146.44B). The key difference: Intuitive Surgical, Inc. is far larger — about 3× Edwards Lifesciences Corporation Common Stock's market cap, and Edwards Lifesciences Corporation Common Stock is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| EW | ISRG | |
|---|---|---|
Market Cap | $49.44B | $146.44B |
Volume | 3,508,027 | 1,895,430 |
Sector | Health | Health |
52-Week High | $95.18 | $592.85 |
52-Week Low | $72.65 | $332.02 |
Enterprise Value | $45.90B | $141.22B |
Typical Hold Time | — | 84 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Intuitive Surgical (ISRG) trades at $415.41, up 2.63% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $10.06B and net income of $2.86B, maintaining impressive 28.45% net margins. Recent earnings beats and expansion into new markets like India and Japan support growth despite China headwinds. Technical indicators show the stock trading near pivot point resistance at $414 with support at $411.
ISRG presents a compelling growth story with dominant robotics positioning and expanding international footprint. The 17% selloff creates opportunity with 16% upside to consensus target of $480.78. Key risks include competitive pressures in robotic surgery and procedure growth normalization. Analyst consensus remains strongly bullish with 70% buy ratings, though valuation multiples remain elevated at P/E of 47.54.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →